Related Experiment Videos
Deficiencies of C1 inhibitor
1The CBR Institute for Biomedical Research, 800 Huntington Avenue, Boston, MA 02115, USA. rosen@cbr.med.harvard.edu
Best Practice & Research. Clinical Gastroenterology
|April 19, 2005
Summary
Deficiencies in C1 inhibitor (C1INH) cause angioedema. While androgens help prevent attacks, effective treatments for acute episodes are still under development, with new drugs in trials.
Area of Science:
- Immunology
- Genetics
- Hematology
Background:
- C1 inhibitor (C1INH) deficiencies lead to angioedema affecting skin, GI tract, or airway.
- Hereditary angioedema stems from genetic C1INH defects.
- Acquired C1INH deficiency can result from auto-antibodies or anti-idiotypic antibodies in B cell lymphoproliferative diseases.
Purpose of the Study:
- To summarize the causes and manifestations of C1 inhibitor deficiencies.
- To discuss current prophylactic strategies and the status of acute attack treatments for angioedema.
Main Methods:
- Literature review of C1 inhibitor deficiency and angioedema.
- Analysis of genetic and acquired causes.
- Overview of treatment approaches, including prophylaxis and investigational therapies.
Main Results:
- C1INH deficiency is the primary cause of angioedema.
- Androgens are effective in preventing angioedema attacks.
- No universally approved treatment exists for acute angioedema attacks, but promising drugs are in late-stage trials.
Conclusions:
- C1 inhibitor deficiency is a key factor in angioedema development.
- Androgen therapy offers prophylaxis for angioedema.
- Further research and clinical trials are crucial for developing effective acute treatments for angioedema.